Regentis Biomaterials Ltd（RGNT）股票分析

$1.180

+0.010 (+0.85%)收盤時

Loading chart…

最高: 1.220
開盤: 1.172
成交量加權均價: 1.19
成交量: 23.20K
市值: —
最低: 1.160
成交金額: 27.53K
企業價值/稅息折舊攤銷前利潤（TTM）: 0.00

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

www.regentis.co.il

AI 分析 of Regentis Biomaterials Ltd (RGNT)

賣出

Regentis Biomaterials Ltd is not a good buy right now due to its extremely low RSI of 26.439, indicating oversold conditions, and a staggering year-to-date decline of 82.49%.

估值指標

Regentis Biomaterials Ltd（RGNT）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。

預期本益比

嚴重低估

5 年均值 P/E

0.00

目前P/E

0.00

高估

0.00

低估

0.00

預期 EV/EBITDA

嚴重低估

5 年均值 EV/EBITDA

0.00

目前EV/EBITDA

0.00

高估

0.00

低估

0.00

預期股價營收比

嚴重低估

5 年均值 P/S

0.00

目前P/S

0.00

高估

0.00

低估

0.00

事件時間軸

2026-10-12 (ET)